POSB197 Impact of Immune Checkpoint Inhibitors (ICIS) on the Management of Advanced Non-Small Cell Lung Cancer (NSCLC) in Real-World Practice at Karolinska University Hospital, Stockholm between 2012 and 2018

In Sweden, ICIs have been reimbursed since 2015 for locally advanced/metastatic NSCLC. ICI monotherapy has been used as second-line (2L) treatment for squamous carcinoma (SQ) since December 2015, for non-squamous carcinoma (NSQ) since June 2016, and as first-line (1L) treatment for high programmed death-ligand-1 (PD-L1) expressors (≥50%) since March 2017. This study from the SCAN LEAF project, part of the I-O Optimise initiative, assessed the early use of ICIs for the real-world management of advanced/metastatic NSCLC.